LY2216684 + albuterol

**LY2216684 + albuterol** is a combination of two drugs: LY2216684 (also known as edivoxetine), a selective norepinephrine reuptake inhibitor primarily researched for major depressive disorder, and albuterol, a widely used short-acting beta-2 adrenergic receptor agonist indicated for the treatment of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). The combination does not currently correspond to a marketed product or established therapeutic regimen. LY2216684 increases norepinephrine levels in the central nervous system by inhibiting its reuptake, potentially offering antidepressant effects, while albuterol acts on beta-2 adrenergic receptors in airway smooth muscle, leading to bronchodilation and relief of bronchospasm.

Other names

edivoxetine + albuterol